低剂量冠状动脉内阿替普酶对急性心肌梗死直接PCI术中微血管阻塞的影响:一项随机临床试验
该研究为1:1:1剂量探索随机临床试验,纳入英国11家医院440例症状发作6小时内、因主要冠状动脉近中段闭塞导致STEMI的患者。患者随机接受安慰剂(n=151)、阿替普酶10 mg(n=144)或阿替普酶20 mg(n=145),在直接PCI期间、梗死相关动脉再灌注后、支架植入前手动输注5至10分钟。主要终点为入组后第2至7天心脏磁共振显示的微血管阻塞量(左心室质量百分比)。20 mg阿替普酶组与安慰剂组微血管阻塞无显著差异(3.5% vs 2.3%;估计差值1.16%;95%CI -0.08%至2.41%;P=0.32),10 mg组与安慰剂组亦无显著差异(2.6% vs 2.3%;估计差值0.29%;95%CI -0.76%至1.35%;P=0.74)。主要不良心脏事件在三组分别为安慰剂组15例(10.1%)、10 mg组18例(12.9%)、20 mg组12例(8.2%)。研究因预设无效性标准提前终止。
要点
- 在症状发作6小时内就诊的急性STEMI患者中,直接PCI术中辅助性冠状动脉内阿替普酶20 mg未减少微血管阻塞(3.5% vs 安慰剂2.3%;估计差值1.16%;95%CI -0.08%至2.41%;P=0.32)。
- 阿替普酶10 mg同样未减少微血管阻塞(2.6% vs 安慰剂2.3%;估计差值0.29%;95%CI -0.76%至1.35%;P=0.74)。
- 主要不良心脏事件(心源性死亡、非致死性心肌梗死、心力衰竭非计划住院)发生率:安慰剂组10.1%(15例)、10 mg组12.9%(18例)、20 mg组8.2%(12例)。
- 研究因预设无效性标准提前终止:基于前267例随机患者的预设分析,两个治疗组主要终点的条件把握度均低于30%。
- 作者结论认为,研究结果不支持在直接PCI术中辅助使用低剂量冠状动脉内阿替普酶以减少微血管阻塞。
适用人群与场景
- 英国11家医院连续纳入的症状发作6小时内就诊的急性STEMI患者,因主要冠状动脉近中段闭塞接受直接PCI。
- 随机分组后随访至3个月,440例中396例(90%)完成主要终点评估,17例(3.9%)退出。
处置流程与药物剂量
- 阿替普酶10 mg或20 mg在直接PCI期间、梗死相关动脉再灌注后、支架植入前经冠状动脉手动输注5至10分钟。
- 研究方案为1:1:1随机分配至安慰剂、阿替普酶10 mg或阿替普酶20 mg。
研究设计与关键结果
- 研究类型:1:1:1剂量探索随机临床试验,11家医院,440例患者,平均年龄60.5岁,女性占15%。
- 主要终点:20 mg阿替普酶组微血管阻塞3.5% vs 安慰剂组2.3%(估计差值1.16%;95%CI -0.08%至2.41%;P=0.32),无显著差异。
- 次要分析:10 mg阿替普酶组微血管阻塞2.6% vs 安慰剂组2.3%(估计差值0.29%;95%CI -0.76%至1.35%;P=0.74),无显著差异。
- 主要不良心脏事件:安慰剂组15例(10.1%)、10 mg阿替普酶组18例(12.9%)、20 mg阿替普酶组12例(8.2%)。
- 研究因预设无效性标准提前终止:前267例随机患者的预设分析显示两个治疗组主要终点条件把握度均低于30%。
证据类型、等级与局限
- 证据类型:随机临床试验。
- 试验注册号:ClinicalTrials.gov NCT02257294。
- 局限:研究因预设无效性标准提前终止;原文未报告其他局限性。
对床旁实践的改变
- 作者结论认为,在症状发作6小时内就诊的急性STEMI患者中,直接PCI术中辅助性低剂量冠状动脉内阿替普酶未能减少微血管阻塞,研究结果不支持该治疗。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Microvascular obstruction commonly affects patients with acute ST-segment elevation myocardial infarction (STEMI) and is associated with adverse outcomes.
OBJECTIVE: To determine whether a therapeutic strategy involving low-dose intracoronary fibrinolytic therapy with alteplase infused early after coronary reperfusion will reduce microvascular obstruction.
DESIGN, SETTING, AND PARTICIPANTS: Between March 17, 2016, and December 21, 2017, 440 patients presenting at 11 hospitals in the United Kingdom within 6 hours of STEMI due to a proximal-mid-vessel occlusion of a major coronary artery were randomized in a 1:1:1 dose-ranging trial design. Patient follow-up to 3 months was completed on April 12, 2018.
INTERVENTIONS: Participants were randomly assigned to treatment with placebo (n = 151), alteplase 10 mg (n = 144), or alteplase 20 mg (n = 145) by manual infusion over 5 to 10 minutes. The intervention was scheduled to occur early during the primary PCI procedure, after reperfusion of the infarct-related coronary artery and before stent implant.
MAIN OUTCOMES AND MEASURES: The primary outcome was the amount of microvascular obstruction (% left ventricular mass) demonstrated by contrast-enhanced cardiac magnetic resonance imaging (MRI) conducted from days 2 through 7 after enrollment. The primary comparison was the alteplase 20-mg group vs the placebo group; if not significant, the alteplase 10-mg group vs the placebo group was considered a secondary analysis.
RESULTS: Recruitment stopped on December 21, 2017, because conditional power for the primary outcome based on a prespecified analysis of the first 267 randomized participants was less than 30% in both treatment groups (futility criterion). Among the 440 patients randomized (mean age, 60.5 years; 15% women), the primary end point was achieved in 396 patients (90%), 17 (3.9%) withdrew, and all others were followed up to 3 months. In the primary analysis, the mean microvascular obstruction did not differ between the 20-mg alteplase and placebo groups (3.5% vs 2.3%; estimated difference, 1.16%; 95% CI, -0.08% to 2.41%; P = .32) nor in the analysis of 10-mg alteplase vs placebo groups (2.6% vs 2.3%; estimated difference, 0.29%; 95% CI, -0.76% to 1.35%; P = .74). Major adverse cardiac events (cardiac death, nonfatal MI, unplanned hospitalization for heart failure) occurred in 15 patients (10.1%) in the placebo group, 18 (12.9%) in the 10-mg alteplase group, and 12 (8.2%) in the 20-mg alteplase group.
CONCLUSIONS AND RELEVANCE: Among patients with acute STEMI presenting within 6 hours of symptoms, adjunctive low-dose intracoronary alteplase given during the primary percutaneous intervention did not reduce microvascular obstruction. The study findings do not support this treatment.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02257294.
参考来源
- McCartney PJ, Eteiba H, Maznyczka AM, et al. Effect of Low-Dose Intracoronary Alteplase During Primary Percutaneous Coronary Intervention on Microvascular Obstruction in Patients With Acute Myocardial Infarction: A Randomized Clinical Trial. JAMA. 2019. PMID: 30620371. doi:10.1001/jama.2018.19802
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。